Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
暂无分享,去创建一个
S. Steinberg | P. Choyke | M. Walther | G. Weiss | N. Dawson | C. Stein | M. Uhrich | M. Cooper | C. Myers | C. Stein | R. Larocca | C. Myers | S. Steinberg | M. Cooper
[1] W. Linehan,et al. Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.
[2] R. Wittes. Manual of oncologic therapeutics , 1991 .
[3] O. Yoshida,et al. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. , 1990, The Journal of urology.
[4] M. Pollak,et al. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. , 1990, Journal of the National Cancer Institute.
[5] G. H. Weiss,et al. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. , 1990, The Journal of clinical endocrinology and metabolism.
[6] M. Dalakas,et al. Suramin‐induced polyneuropathy , 1990, Neurology.
[7] G. Mills,et al. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. , 1990, Cancer research.
[8] K. Huang,et al. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. , 1990, The Journal of biological chemistry.
[9] H. Sutton,et al. Effect of external beam radiation therapy on serum prostate-specific antigen. , 1990, Urology.
[10] P. Leder,et al. The int‐2 gene product acts as an epithelial growth factor in transgenic mice. , 1990, The EMBO journal.
[11] M. Jaye,et al. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia , 1990, The Prostate.
[12] N. Quarto,et al. Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin , 1989, The Journal of cell biology.
[13] S. Shain,et al. Differences in responsiveness of clonally derived AXC/SSh rat prostate cancer cells to secreted or prototypic mitogens. , 1989, Cancer research.
[14] T. Stamey,et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.
[15] C. Stein,et al. Suramin: an anticancer drug with a unique mechanism of action. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Barak,et al. Prognostic importance of the rate of decrease in prostate specific antigen (PSA) levels after treatment of patients with carcinoma of prostate , 1989 .
[17] R. Lawson,et al. Cultured human prostate‐derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor , 1989, The Prostate.
[18] M. Keating,et al. Ligand activation causes a phosphorylation-dependent change in platelet-derived growth factor receptor conformation. , 1988, The Journal of biological chemistry.
[19] W. Catalona,et al. Differences in values obtained with 2 assays of prostate specific antigen. , 1988, The Journal of urology.
[20] C. Stein,et al. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. , 1988, Blood.
[21] J. Michaeli,et al. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma , 1988, The Prostate.
[22] M. Eisenberger. Chemotherapy for prostate carcinoma. , 1988, NCI monographs : a publication of the National Cancer Institute.
[23] T. Stamey,et al. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .
[24] J. Oesterling,et al. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. , 1987, Clinical chemistry.
[25] R. Coffey,et al. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.
[26] G. Chrousos,et al. Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey. , 1987, The Journal of clinical endocrinology and metabolism.
[27] H. Scher,et al. Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors. , 1987, The American journal of medicine.
[28] W. Linehan,et al. Human prostate carcinoma causes hypercalcemia in athymic nude mice and produces a factor with parathyroid hormone-like bioactivity. , 1986, The Journal of urology.
[29] E. Gelmann,et al. Suramin and function of the adrenal cortex. , 1986, Annals of internal medicine.
[30] R. Redfield,et al. Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection , 1986, Journal of clinical pharmacology.
[31] G. Chrousos,et al. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. , 1986 .
[32] S. Coughlin,et al. Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[33] V. Farewell,et al. Using and Understanding Medical Statistics , 1984 .
[34] M. Lavin,et al. Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. , 1984, The Journal of biological chemistry.
[35] M. Sporn,et al. Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.
[36] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[37] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .